Vesper Bio bags Michael J Fox Foundation grant to assess sortilin inhibitor impact in Parkinson’s

Targeting sortilin to rebalance progranulin levels thought to hold promise in CNS diseases, including Parkinson’s.
Danish biotech Vesper Bio revealed it has been awarded a grant worth approximately $873,000 by The Michael J Fox Foundation for Parkinson’s Research (MJFF). The Copenhagen-based company specializes in sortilin receptor biology will use the funding to facilitate the assessment of sortilin inhibitors in the treatment of Parkinson’s disease.

The research initiative, set to kick off this month, falls under the MJFF’s Parkinson’s Disease Therapeutics preclinical pipeline program, which supports promising therapeutic developments with the potential to prevent, stop, or delay Parkinson’s disease progression or alleviate daily symptoms.

Sortilin receptor biology is linked to diseases of the central nervous system, eye, cardiovascular system, dyslipidaemias, and oncology. Vesper’s approach involves targeting sortilin actions specifically at the cell membrane, differentiating it from methods that modulate intracellular trafficking of proteins.

Vesper Bio bags Michael J Fox Foundation grant to assess sortilin inhibitor impact in Parkinson’s